Figures & data
Table 1. Patient characteristics.
Table 2. Treatment patterns.
Figure 1. Time from ceritinib initiation to first dose reduction – among patients who initiated ceritinib on 750 mg dose. 1Number of patients at risk of having a dose reduction after elapsed time (still observed). Patients were observed from the ceritinib initiation until the first dose reduction, ceritinib treatment discontinuation, or end of continuous eligibility, whichever occurred first. CI: confidence interval.
Figure 2. Time to ceritinib discontinuation. 1Number of patients at risk of discontinuing ceritinib therapy after elapsed time (still observed). Patients were observed from ceritinib initiation until ceritinib discontinuation or end of continuous eligibility, whichever occurred first. If a patient had less than 30 days of continuous eligibility after ceritinib discontinuation, the patient was censored at the last day of supply of the last prescription fill for ceritinib. CI: confidence interval.
Table 3. Ceritinib dose modification patterns.
Table 4. Description of healthcare resource utilization during the observation period after ceritinib initiation.
Table 5. Description of healthcare costs during the observation period after ceritinib initiation.